Related Experiment Video
Updated: Jun 24, 2025

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease
Ricardo G Suarez1, Namitha Guruprasad2, Ganesh Tata2
1Department of Paediatrics, University of Alberta, Edmonton, AB, Canada.
Insights
Serum metabolites like tryptophan and glutarylcarnitine are linked to inflammation in paediatric Crohn disease (pCD). These findings may help understand pCD and assess disease severity.
Area of Science:
- Biochemistry
- Gastroenterology
- Metabolomics
Background:
- Paediatric Crohn disease (pCD) involves complex inflammatory processes.
- Identifying biomarkers for inflammation is crucial for disease management.
Purpose of the Study:
- To identify serum metabolites associated with mucosal and transmural inflammation in pediatric Crohn disease (pCD).
Main Methods:
- Serum metabolites were analyzed in 56 pCD patients using liquid chromatography/mass spectrometry.
- Random forest models and mRMR feature selection were employed to identify key metabolites.
- Disease activity was assessed using the Paediatric Inflammatory Crohn magnetic resonance enterography Index (PICMI), simple endoscopic score (SES), fecal calprotectin (FCP), and C-reactive protein (CRP).
Main Results:
- Tryptophan and glutarylcarnitine were identified as top metabolites associated with pCD inflammation.
- Amino acids and amines were influential in predicting transmural and mucosal inflammation, with models achieving an AUC > 70%.
- Metabolite associations pointed to disruptions in the TCA cycle, aminoacyl-tRNA biosynthesis, and tryptophan, butanoate, and tyrosine metabolism.
Conclusions:
- Serum metabolite profiles differ between healthy controls and Crohn disease patients.
- Specific serum metabolites are associated with transmural and mucosal inflammation in pCD.
- These identified metabolites offer potential for understanding pCD pathogenesis and improving disease severity assessment.
Background And Aims:
We aimed to identify serum metabolites associated with mucosal and transmural inflammation in paediatric Crohn disease [pCD].
Methods:
In all, 56 pCD patients were included through a pre-planned sub-study of the multicentre, prospective, ImageKids cohort, designed to develop the Paediatric Inflammatory Crohn magnetic resonance enterography [MRE] Index [PICMI]. Children were included throughout their disease course when undergoing ileocolonoscopy and MRE and were followed for 18 months, when MRE was repeated. Serum metabolites were identified using liquid chromatography/mass spectroscopy. Outcomes included: PICMI, the simple endoscopic score [SES], faecal calprotectin [FCP], and C-reactive protein [CRP], to assess transmural, mucosal, and systemic inflammation, respectively. Random forest models were built by outcome. Maximum relevance minimum redundancy [mRMR] feature selection with a j-fold cross-validation scheme identified the best subset of features and hyperparameter settings.
Results:
Tryptophan and glutarylcarnitine were the top common mRMR metabolites linked to pCD inflammation. Random forest models established that amino acids and amines were among the most influential metabolites for predicting transmural and mucosal inflammation. Predictive models performed well, each with an area under the curve [AUC] > 70%. In addition, serum metabolites linked with pCD inflammation mainly related to perturbations in the citrate cycle [TCA cycle], aminoacyl-tRNA biosynthesis, tryptophan metabolism, butanoate metabolism, and tyrosine metabolism.
Conclusions:
We extend on recent studies, observing differences in serum metabolites between healthy controls and Crohn disease patients, and suggest various associations of serum metabolites with transmural and mucosal inflammation. These metabolites could improve the understanding of pCD pathogenesis and assessment of disease severity.
More Related Videos
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents